Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 14630515 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | beryllium disease | NA | NA | NA | unclassified | |
| the pathobiology of chronic beryllium disease (cbd) involves the major histocompatibility complex class ii human leukocyte antigen (hla). | |||||||
| 14662898 | MHC (MHC) | beryllium disease | NA | NA | NA | unclassified | |
| influence of mhc class ii in susceptibility to beryllium sensitization and chronic beryllium disease. | |||||||
| 14662898 | HLA-DPB1 (HLA-DPB1) | beryllium disease | NA | NA | NA | unclassified | |
| a glutamic acid at residue 69(glu(69)) in the hla-dpb1 gene (glu(69)) is associated with chronic beryllium disease (cbd) and possibly beryllium sensitization (bes). | |||||||
| 15273960 | HLA (HLA) | beryllium disease | NA | NA | NA | unclassified | |
| the association between hla-dpb1glu69 and chronic beryllium disease and beryllium sensitization. | |||||||
| 15273960 | HLA-DPB1 (HLA-DPB1) | beryllium disease | NA | NA | NA | unclassified | |
| several case-control studies have found an association between chronic beryllium disease (cbd) and hla-dpb1 gene variants. | |||||||
| 15273960 | HLA-DPB1 (HLA-DPB1) | occupational disease | NA | NA | NA | unclassified | |
| follow-up of this cohort, scrutiny of hla-dpb1 haplotypes, and evaluation of gene-environment and gene-gene interactions will be important for fully understanding the immunogenetic nature of this occupational disease. | |||||||
| 16054169 | HLA (HLA) | beryllium disease | NA | NA | NA | unclassified | |
| it was shown that anti-hla antibodies could block the beryllium-specific response in the beryllium lymphocyte proliferation test, thereby implicating hla genes in chronic beryllium disease. | |||||||
| 16054169 | HLA-DPB1 (HLA-DPB1) | beryllium disease | NA | NA | NA | positive | |
| a supratypic genetic marker, hla-dpb1*e69, was found to be strongly associated with immunologic sensitization to beryllium and chronic beryllium disease in beryllium workers. | |||||||
| 16054169 | HLA-DPB1 (HLA-DPB1) | beryllium disease | NA | NA | NA | positive | |
| the purpose of the study was to evaluate the evidence for potential differential susceptibility that may be associated with the physical characteristics of hla protein molecules for which different hla-dpb1*e69 variants code; that is, do some hla-dpb1*e69 variants convey higher risk of beryllium sensitization and chronic beryllium disease than others. | |||||||
| 16054169 | HLA-DPB1*17 | beryllium disease | NA | NA | NA | unclassified | |
| among the 40 hla-dpb1 gene variants that code for e69, molecular epidemiological studies have suggested a risk hierarchy, where some variants appear to convey low to moderate risk of chronic beryllium disease (e.g., hla-dpb1*0201, approximately 3-fold increased risk), some convey an intermediate risk (e.g., hla-dpb1*1901, approximately 5-fold) and others convey high risk (e.g., hla-dpb1*1701, >10-fold). | |||||||
Copyright 2024